Lexicon Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 1, 2024

Rhea-AI Summary

Lexicon Pharmaceuticals (Nasdaq: LXRX) has announced its upcoming second quarter 2024 financial results conference call and webcast, scheduled for August 1, 2024, after market close. The company will host a conference call and live webcast at 5:00 p.m. ET (4:00 p.m. CT) to discuss financial results and provide a business update.

Investors can access the call using the following details:

• U.S. Dial-in: (888) 317-6003
• International Dial-in: (412) 317-6061
• Conference ID: 7023126

A dial-in replay will be available for 7 days, and an audio webcast replay will be accessible for 14 days after the call at www.lexpharma.com/events.

THE WOODLANDS, Texas, July 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its second quarter 2024 financial results on Thursday, August 1, 2024 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00 p.m. CT) that day to discuss the financial results and to provide a business update.

Dial-in Information
U.S. Dial-in Number: (888) 317-6003
International Dial-in Number: (412) 317-6061
Conference ID: 7023126

Replay Information
U.S. Dial-in Number: (877) 344-7529
Replay International Dial-in Number: (412) 317-0088
Conference ID: 3907883

The dial-in replay will be available for 7 days following the call. An audio webcast will be available online at www.lexpharma.com/events, with a webcast replay accessible for 14 days after the call.

About Lexicon Pharmaceuticals 
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through its Genome5000™ program, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon is commercially launching one of these medicines, INPEFA^® (sotagliflozin) in the United States, and has a pipeline of other promising drug candidates in discovery and clinical and preclinical development in neuropathic pain, diabetes and metabolism and other indications.  For additional information, please visit www.lexpharma.com. 

Safe Harbor Statement 

This press release contains “forward-looking statements,” including statements relating to Lexicon’s financial position and long-term outlook on its business, growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including Lexicon’s ability to meet its capital requirements, successfully commercialize INPEFA in heart failure on the timeline and/or at the prices currently contemplated or at all, conduct preclinical and clinical development and obtain necessary regulatory approvals of sotagliflozin (in other indications), LX9211, LX9851 and its other drug candidates on its anticipated timelines, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates. Any of these risks, uncertainties and other factors may cause Lexicon’s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under “Risk Factors” in Lexicon’s annual report on Form 10-K for the year ended December 31, 2023 and other subsequent disclosure documents filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise. 

For Investor Inquiries: 
Lisa DeFrancesco  
Lexicon Pharmaceuticals, Inc.         
lexinvest@lexpharma.com 

For Media Inquiries:
Alina Cocuzza
Lexicon Pharmaceuticals, Inc.
acocuzza@lexpharma.com

FAQ

When will Lexicon Pharmaceuticals (LXRX) release its Q2 2024 financial results?

Lexicon Pharmaceuticals (LXRX) will release its second quarter 2024 financial results on Thursday, August 1, 2024, after the markets close.

What time is Lexicon Pharmaceuticals' (LXRX) Q2 2024 earnings call scheduled for?

Lexicon Pharmaceuticals' (LXRX) Q2 2024 earnings call is scheduled for 5:00 p.m. ET (4:00 p.m. CT) on August 1, 2024.

How can investors access Lexicon Pharmaceuticals' (LXRX) Q2 2024 earnings call?

Investors can access Lexicon Pharmaceuticals' (LXRX) Q2 2024 earnings call by dialing (888) 317-6003 (U.S.) or (412) 317-6061 (International) with Conference ID: 7023126.

How long will the replay of Lexicon Pharmaceuticals' (LXRX) Q2 2024 earnings call be available?

The dial-in replay of Lexicon Pharmaceuticals' (LXRX) Q2 2024 earnings call will be available for 7 days, while the audio webcast replay will be accessible for 14 days after the call.